Literature DB >> 31912270

[Technical aspects of quality assurance for intravitreal injections (IVI)].

F Bucher1, P Mussinghoff2, T Kühn3, A Stahl4, D Böhringer5.   

Abstract

BACKGROUND: Successful quality assurance in intravitreal injection (IVI) of medications requires a complex information technology infrastructure. The main challenges are data availability independent of location, standardization of clinical data, integration of extensive and currently non-standardized image documentation from coherence tomography and compliance with data protection regulations.
OBJECTIVE: In this article the technical implementation and data protection principles are reviewed.
MATERIAL AND METHODS: Essential aspects in the implementation of quality assurance in the field of IVI are discussed in a systematic approach.
RESULTS: In the field of network architectures web-based applications supplemented by local virtual private networks (VPN) and/or other software instances have recently replaced the previously commonly used physical data medium exchange. The standardization of the data, e.g. by converting the visual acuity into logMAR, plays an important role in the collection of treatment data. Multiple non-standardized data formats in optical coherence tomography complicate the general quality assurance structure and comparability of data.
CONCLUSION: International standards will probably facilitate this in the near future. Until then individual solutions have to be found on site.

Keywords:  Data availability; Data protection; Network architecture; Standardized data formats; Treatment data

Mesh:

Year:  2020        PMID: 31912270     DOI: 10.1007/s00347-019-01029-w

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  8 in total

Review 1.  Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors.

Authors:  Hemal Mehta; Adnan Tufail; Vincent Daien; Aaron Y Lee; Vuong Nguyen; Mehmet Ozturk; Daniel Barthelmes; Mark C Gillies
Journal:  Prog Retin Eye Res       Date:  2018-01-02       Impact factor: 21.198

Review 2.  Clinical Registries in Ophthalmology.

Authors:  Jeremy C K Tan; Alexander C Ferdi; Mark C Gillies; Stephanie L Watson
Journal:  Ophthalmology       Date:  2018-12-17       Impact factor: 12.079

3.  [Reasons for delayed and discontinued therapy in age-related macular degeneration].

Authors:  M W M Wintergerst; J Bouws; J Loss; B Heimes; D Pauleikhoff; F G Holz; R P Finger
Journal:  Ophthalmologe       Date:  2018-12       Impact factor: 1.059

4.  ASSESSING THE ACCURACY OF A LARGE OBSERVATIONAL REGISTRY OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Authors:  Vuong Nguyen; King Fai Calvin Leung; Chu Luan Nguyen; David Squirrell; Rohan Essex; Jennifer Arnold; Stephanie Young; Daniel Barthelmes; Mark Gillies
Journal:  Retina       Date:  2020-05       Impact factor: 4.256

5.  Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment.

Authors:  Thomas Wecker; Bastian Grundel; Sabine Reichl; Milena Stech; Clemens Lange; Hansjürgen Agostini; Daniel Böhringer; Andreas Stahl
Journal:  Sci Rep       Date:  2019-03-01       Impact factor: 4.379

6.  Comparison of two data collection processes in clinical studies: electronic and paper case report forms.

Authors:  Anaïs Le Jeannic; Céline Quelen; Corinne Alberti; Isabelle Durand-Zaleski
Journal:  BMC Med Res Methodol       Date:  2014-01-17       Impact factor: 4.615

7.  Creation of an Accurate Algorithm to Detect Snellen Best Documented Visual Acuity from Ophthalmology Electronic Health Record Notes.

Authors:  Michael Mbagwu; Dustin D French; Manjot Gill; Christopher Mitchell; Kathryn Jackson; Abel Kho; Paul J Bryar
Journal:  JMIR Med Inform       Date:  2016-05-04

8.  Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study.

Authors:  Frank G Holz; Ramin Tadayoni; Stephen Beatty; Alan Berger; Matteo Giuseppe Cereda; Philip Hykin; Giovanni Staurenghi; Kim Wittrup-Jensen; Andreas Altemark; Jonas Nilsson; Kun Kim; Sobha Sivaprasad
Journal:  Br J Ophthalmol       Date:  2016-03-30       Impact factor: 4.638

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.